DBI 6014

Drug Profile

DBI 6014

Alternative Names: DI 6014; Fully human monoclonal antibody - DBI 6014

Latest Information Update: 23 Feb 2005

Price : $50

At a glance

  • Originator Abgenix; Diabetogen Biosciences
  • Developer Diabetogen Biosciences
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Type 1 diabetes mellitus

Most Recent Events

  • 23 Feb 2005 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
  • 14 Jan 2003 DPI 6014 is available for licensing [www.diabetogen.com]
  • 14 Jan 2003 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top